about
American Brain Tumor Association Adolescent and Young Adult Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012.Anti-N-methyl-D-aspartate receptor-mediated encephalitis in infants and toddlers: case report and review of the literature.Alex's Lemonade Stand Foundation Infant and Childhood Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2007-2011.Trends in central nervous system tumor incidence relative to other common cancers in adults, adolescents, and children in the United States, 2000 to 2010.Years of life lived with disease and years of potential life lost in children who die of cancer in the United States, 2009Trends in Clostridium difficile infection and risk factors for hospital acquisition of Clostridium difficile among children with cancer.Impact of vision loss among survivors of childhood central nervous system astroglial tumors.Variation in Risk of Hospital-Onset Clostridium difficile Infection Across β-Lactam Antibiotics in Children With New-Onset Acute Lymphoblastic Leukemia.Fractional anisotropy of the optic radiations is associated with visual acuity loss in optic pathway gliomas of neurofibromatosis type 1.fdg-pet in two cases of neurofibromatosis type 1 and atypical malignancies.Incidence and survival trends for medulloblastomas in the United States from 2001 to 2013.Neurocognitive outcomes in neurofibromatosis clinical trials: Recommendations for the domain of attentionChoroid plexus tumors in adult and pediatric populations: the Cleveland Clinic and University Hospitals experience.Systemic Chemotherapy and White Matter Integrity in Tracts Associated with Cognition Among Children With Neurofibromatosis Type 1.Validation of an automated tractography method for the optic radiations as a biomarker of visual acuity in neurofibromatosis-associated optic pathway glioma.Effects of genetic background on cardiovascular anomalies in the Ts16 mouse.Childhood Cancer and Brain Tumor Late Effects: Relationships with Family Burden and Survivor Psychological Outcomes.2016 Children's Tumor Foundation conference on neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosis.Optic Pathway Gliomas in Neurofibromatosis Type 1: An Update: Surveillance, Treatment Indications, and Biomarkers of Vision.A rare case of ectopic recurrence of a craniopharyngioma diagnosed 17 years after initial presentationManagement of pediatric low-grade gliomaTumor Response Assessment in Diffuse Intrinsic Pontine Glioma: Comparison of Semiautomated Volumetric, Semiautomated Linear, and Manual Linear Tumor Measurement StrategiesMolecular markers and targeted therapy in pediatric low-grade glioma
P50
Q30366918-FE2DADD9-4B6C-49F4-8A4D-85478758B075Q30710506-D8198BA7-836C-47F0-AB21-2F2B6D3AE1ECQ34776024-D7EB4C78-C6D8-419A-958F-3F22C8539927Q34982039-F707DCD8-6EB8-4252-AE0F-648243F67C7DQ35469475-5F9C9BB6-A2D2-4699-A9D8-B546153651BAQ35997157-69CD996D-5F77-4050-BDEF-5F918BD87D09Q36609635-9C0B9F59-52FC-4466-AE07-A588B08E8AC1Q36862305-24BD01A8-5E83-4522-A5FA-370F88722C7EQ37021573-D56A1C80-9234-4910-BA7F-F02547CB87E1Q37719642-9B07F943-90E4-4FCD-B47A-8BB11879D876Q38614779-5AC43641-472B-4AFC-8D30-7782F1E31CB3Q38831064-2A2F041D-DD82-45DD-A05C-34E1CA891995Q38909961-4B99BFB6-CC4B-4040-86CD-9EEB15DB4EC3Q38921864-2622C56B-EA87-465B-9B15-F067244F27B2Q39354974-D8EF445F-6094-40B4-B91F-C8A83FCD55CEQ46419766-A0CBD9A9-54B5-478A-A8C5-32B94B5A8C51Q47573525-5347CC02-5819-4094-B9AE-A230990DD165Q53821957-DBB1F997-89A6-4C83-BFF9-9B89B7BB5A1BQ55457767-BF3724E9-83ED-411D-AD0C-A7C01FC01DFBQ84165856-6B34CF4F-3054-4BC2-A106-369490FF69F0Q90367882-2E19D8B6-3985-4172-A602-4D6E5CA2EEE8Q94472841-36D93528-D889-46BC-BB60-9C7E18A59277Q94603984-2496A682-B950-4AAC-882E-8ED1065EB7EF
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Peter De Blank
@ast
Peter De Blank
@en
Peter De Blank
@es
Peter De Blank
@nl
Peter De Blank
@sl
type
label
Peter De Blank
@ast
Peter De Blank
@en
Peter De Blank
@es
Peter De Blank
@nl
Peter De Blank
@sl
prefLabel
Peter De Blank
@ast
Peter De Blank
@en
Peter De Blank
@es
Peter De Blank
@nl
Peter De Blank
@sl
P106
P1153
6505522268
P21
P31
P496
0000-0001-6623-3040